Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

22.82
+1.004.58%
Volume:336.53K
Turnover:7.66M
Market Cap:1.47B
PE:-6.58
High:23.06
Open:22.16
Low:22.16
Close:21.82
52wk High:23.06
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.47
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.56
PE(LYR):-6.13

Loading ...

Cullinan Therapeutics Inc: Sales Agreement Prospectus Covers Offering of up to $200 Mln of Common Stock

THOMSON REUTERS
·
Apr 28

FDA accepts Cullinan partner zipalertinib NDA for EGFR exon 20 NSCLC

Reuters
·
Apr 28

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations

THOMSON REUTERS
·
Apr 28

Cullinan Therapeutics Inc - Prescription Drug User Fee Act (Pdufa) Target Action Date Is February 27, 2027

THOMSON REUTERS
·
Apr 28

Cullinan Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 28

JonesTrading Sticks to Their Buy Rating for Cullinan Management (CGEM)

TIPRANKS
·
Apr 07

Morgan Stanley Sticks to Their Buy Rating for Cullinan Management (CGEM)

TIPRANKS
·
Mar 16

Stifel Nicolaus Sticks to Their Buy Rating for Cullinan Management (CGEM)

TIPRANKS
·
Mar 13

Cullinan Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 11

Guggenheim Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
Mar 11

Cullinan: Advancing Immunology and Oncology Pipeline Undervalued; Buy Rating on CLN-978 Catalysts and Strong Cash Runway

TIPRANKS
·
Mar 11

Cullinan Management Adopts Reduced SEC Reporting: Lower Compliance Costs, But Potential Hit to Investor Appeal and Liquidity

TIPRANKS
·
Mar 11

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE)

TIPRANKS
·
Mar 11

Wedbush Adjusts Price Target on Cullinan Therapeutics to $36 From $34, Maintains Outperform Rating

MT Newswires Live
·
Mar 10

Cullinan Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 10

Cullinan Therapeutics FY2025 net loss widens 31% to USD 219.88 million

Reuters
·
Mar 10

Cullinan Therapeutics Q4 EPS $(0.77) Beats $(0.82) Estimate

Benzinga Earnings
·
Mar 10

Earnings Flash (CGEM) Cullinan Therapeutics Posts Q4 Net Loss $0.77 a Share, vs. FactSet Est of $0.77 Loss

MT Newswires Live
·
Mar 10

Cullinan Therapeutics Q4 net loss widens

Reuters
·
Mar 10

BRIEF-Cullinan Therapeutics Q4 Operating Expenses USD 55.259 Million

Reuters
·
Mar 10